Pharma Industry News

AstraZeneca, ZS Pharma overcome manufacturing issues to get potential blockbuster back on track

Written by David Miller

AstraZeneca said its potential blockbuster hyperkalemia drug ZS-9 is back on track after the FDA rejected it in 2016 due to manufacturing issues at its Texas facility.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]